Luminex's Q4 Revenues Climb 51 Percent as Profit Rises on Settlement | GenomeWeb
NEW YORK (GenomeWeb News) – Luminex today reported a 51 percent increase in fourth-quarter revenues and a sharp uptick in profits, due to a settlement payment received during the quarter.
 
The results include the combined operations of Luminex and Tm Bioscience, which Luminex acquired for $44 million last March and renamed Luminex Molecular Diagnostics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.